Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

NCT00671554 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Due to business considerations; not due to toxicities or adverse events.

Conditions

Melanoma

Interventions

BIOLOGICAL: Melaxin (autologous dendritoma vaccine) and BCG

Sponsor

Prisma Health-Upstate

Collaborators

[object Object]